Treatment with carfilzomib. Should these patients be admitted in the Intensive Care Unit?
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España. Electronic address: rakel_20r@hotmail.com.
R
R
Rodríguez-García
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
M J
MJ
Espina
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
L
L
Viña
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
I
I
Astola
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
L
L
López-Amor
Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
D
D
Escudero
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003422:Critical Care; D003907:Dexamethasone / Q000008:administration & dosage; D017809:Fatal Outcome; D006321:Heart / Q000187:drug effects; D006323:Heart Arrest / Q000139:chemically induced* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000628:therapy; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous
D009842:Oligopeptides; D011480:Protease Inhibitors; C524865:carfilzomib; D003907:Dexamethasone; D000077269:Lenalidomide